^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Published date:
01/04/2023
Excerpt:
REGN5093-M114 potently reduced tumor growth of EGFR-mutant NSCLC with PTEN loss or MET Y1230C mutation after progression on prior osimertinib and savolitinib treatment...Altogether, REGN5093-M114 is a promising candidate to overcome the challenges facing functional MET pathway blockade.
DOI:
10.1158/1078-0432.CCR-22-2180